U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Addendum to Psychosis and schizophrenia in children and young people. London: National Institute for Health and Care Excellence (NICE); 2016 May. (Clinical Guideline Addendum, No. 155.1.)

Cover of Addendum to Psychosis and schizophrenia in children and young people

Addendum to Psychosis and schizophrenia in children and young people.

Show details

Appendix KExcluded economic studies

The list of excluded economic studies and the reason for their exclusion is provided in Table 18.

Table 18Excluded economic studies

StudyReason for Exclusion
Achilla,E., McCrone,P., The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. [Review], Applied Health Economics & Health Policy, 11, 95–106, 2013Systematic review, individual studies checked and subsequently excluded because they did not meet the inclusion criteria
Ascher-Svanum,H., Furiak,N.M., Lawson,A.H., Klein,T.M., Smolen,L.J., Conley,R.R., Culler,S.D., Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States, Journal of Medical Economics.15 (3) (pp 531–547), 2012.Date of Publication: June 2012., 531–547, 2012Adult population
Colombo,G.L., Caruggi,M., Di,Matteo S., Rossi,A., An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia.[Erratum appears in Neuropsychiatr Dis Treat. 2008 Dec;4(6):1283], Neuropsychiatric Disease & Treatment, 4, 967–976, 2008Adult population
Einarson,T.R., Hemels,M.E., Validation of an economic model of paliperidone palmitate for chronic schizophrenia, Journal of Medical Economics, 16, 1267–1274, 2013Systematic review, individual studies checked and subsequently excluded because they did not meet the inclusion criteria
Furiak,N.M., Ascher-Svanum,H., Klein,R.W., Smolen,L.J., Lawson,A.H., Conley,R.R., Culler,S.D., Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States, Cost Effectiveness & Resource Allocation, 7, 4-, 2009Adult population
Garcia-Ruiz,A.J., Perez-Costillas,L., Montesinos,A.C., Alcalde,J., Oyaguez,I., Casado,M.A., Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses, Health Economics Review.2 (1) (pp 1–12), 2012.Date of Publication: 2012., 1–12, 2012Adult population
Geitona,M., Kousoulakou,H., Ollandezos,M., Athanasakis,K., Papanicolaou,S., Kyriopoulos,I., Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study, Annals of General Psychiatry, 7, 16-, 2008Adult population
Graham,C.N., Mauskopf,J.A., Lawson,A.H., Ascher-Svanum,H., Bruhn,D., Updating and confirming an industry-sponsored pharmacoeconomic model: Comparing two antipsychotics in the treatment of schizophrenia, Value in Health.15 (1) (pp 55–64), 2012.Date of Publication: January-February 2012., 55–64, 2012Adult population
Kasteng,F., Eriksson,J., Sennfalt,K., Lindgren,P., Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder, Acta psychiatrica Scandinavica, 124, 214–225, 2011Adult population
Kruse,G., Wong,B.J., Duh,M.S., Lefebvre,P., Lafeuille,M.H., Fastenau,J.M., Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment, PharmacoEconomics, 33, 1049–1067, 2015Systematic review, individual studies checked and subsequently excluded because they did not meet the inclusion criteria
Lachaine,J., Beauchemin,C., Mathurin,K., Gilbert,D., Beillat,M., Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada, Journal of Medical Economics.17 (4) (pp 296–304), 2014.Date of Publication: 2014., 296–304, 2014Adult population
Millier,A., Amri,I., Boyer,L., Auquier,P., Toumi,M., Utility decrements associated with side effects in schizophrenia, Journal of Medical Economics.17 (12) (pp 853–861), 2014.Date of Publication: 01 Dec 2014., 853–861, 2014Not cost-effectiveness analysis
O’Day,K., Rajagopalan,K., Meyer,K., Pikalov,A., Loebel,A., Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US, ClinicoEconomics and Outcomes Research.5 (1) (pp 459–470), 2013.Date of Publication: 2013., 459–470, 2013Adult population
Park,T., Kuntz,K.M., Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia, Value in Health.17 (4) (pp 310–319), 2014.Date of Publication: June 2014., 310–319, 2014Adult population
Treur,M., Baca,E., Bobes,J., Canas,F., Salvador,L., Gonzalez,B., Heeg,B., The cost-effectiveness of paliperidone extended release in Spain, Journal of Medical Economics, 15, Suppl-34, 2012Adult population
Von,Scheele B., Mauskopf,J., Brodtkorb,T.-H., Ainsworth,C., Berardo,C.G., Patel,A., Relationship between modeling technique and reported outcomes: Case studies in models for the treatment of schizophrenia, Expert Review of Pharmacoeconomics and Outcomes Research.14 (2) (pp 235–257), 2014.Date of Publication: April 2014., 235–257, 2014Systematic review, individual studies checked and subsequently excluded because they did not meet the inclusion criteria
Zeidler,J., Mahlich,J., Greiner,W., Heres,S., Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.[Erratum appears in Appl Health Econ Health Policy. 2013 Dec;11(6):689], Applied Health Economics & Health Policy, 11, 509–521, 2013Systematic review, individual studies checked and subsequently excluded because they did not meet the inclusion criteria
Copyright © National Institute for Health and Care Excellence 2016.
Bookshelf ID: NBK550757
Contents